EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison

Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, Stefano Vecchia, Luca Cancanelli, Vera Damuzzo, Stefania Gori, Roberto Tessari, Teodoro Sava, Alessandro Inno

Frontiers in Oncology · 08.05.2026 · 16

DOI: 10.3389/fonc.2026.1802008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 08.05.2026. Verfasst von Luna Del Bono und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib (Osi) has long represented the standard first-line treatment for metastatic EGFR-mutated non-small cell lung cancer. Recently, two randomized phase 3 trials demonstrated that osimertinib plus platinum-based chemotherapy (Osi+CT) and amivamtamab plus lazertinib (Ami+Laz) improve outcomes compared with Osi alone, although no direct comparison between these regimens are available. This study aimed to indirectly compare progression-free survival (PFS) and overall survival (OS). Materials and methods Three randomized clinical trials (FLAURA, FLAURA-2, and MARIPOSA) were included following PRISMA guidelines. Individual patient data (IPD) were reconstructed from Kaplan-Meier curves using the IPDfromKM algorithm. Hazard ratios (HR) with 95% confidence intervals (CI) and restricted mean survival time (RMST) were calculated for PFS and OS. Subgroup analyses were performed for patients with central nervous system (CNS) metastases and by EGFR mutation subtypes. A network meta-analysis was conducted to evaluate adverse drug reactions.

Results

In the indirect comparison, Osi+CT and Ami+Laz showed no statistical difference in terms of PFS (HR 0.79, 95% CI 0.61-1.04), with PFS-RMST estimates at 30 months numerically longer with Osi+CT (22.53 vs 20.59 months). No statistically significant differences in OS were observed between regimens (HR 0.95, 95% CI 0.73–1.22). Subgroup PFS analyses according to baseline CNS metastases and EGFR mutation subtypes showed no statistically conclusive differences between regimens. Safety profiles varied: Osi+CT was associated with higher rates of grade ≥ 3 hematologic and gastrointestinal toxicities, while Ami+Laz was linked to higher rates of dermatologic events, infusion-related reactions, hypoalbuminemia, and peripheral edema.

Conclusions

Despite the inherent limitations of indirect comparisons, these findings suggest that Osi+CT and Ami+Laz provide comparable survival benefits, while distinct toxicity profiles may influence therapeutic decision-making in conjunction with patients’ clinical characteristics and preferences.

Schlagwörter

Stichwörter der Autor:innen

EGFR-mutated NSCLCamivantamabfirst-line therapyindirect treatment comparisonlazertinibnetwork meta-analysisosimertinibreconstructed individual patient data

Autor:innen und Institutionen

  • School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Territorial Pharmaceutical Service, Azienda Unità Locale Socio-Sanitaria (ULSS) 8 Berica, Vicenza, Italy.
  • Italian Society of Clinical Pharmacy and Therapeutics, Turin, Italy.
  • Pharmaceutical Department, Unità Sanitaria Locale (USL) Toscana Centro, Prato, Italy.
  • Hospital Pharmacy Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
  • Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy.

Zitieren

APA

Del Bono, L., Ossato, A., Gasperoni, L., Vecchia, S., Cancanelli, L., Damuzzo, V., Gori, S., Tessari, R., Sava, T., & Inno, A. (2026). Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1802008

Vancouver

Del Bono L, Ossato A, Gasperoni L, Vecchia S, Cancanelli L, Damuzzo V, et al. Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1802008

BibTeX
@article{DelBono2026,
  author = {Del Bono, Luna and Ossato, Andrea and Gasperoni, Lorenzo and Vecchia, Stefano and Cancanelli, Luca and Damuzzo, Vera and Gori, Stefania and Tessari, Roberto and Sava, Teodoro and Inno, Alessandro},
  title = {Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1802008}
}
Kostenlos starten →